Jaguar Health Presents Additional Pediatric IF Data, But Financial Crisis Looms

What happened

Jaguar Health presented new data at ESPGHAN 2026 showing crofelemer reduced parenteral support by up to 48% in a single patient with microvillus inclusion disease (MVID), labeling the results 'groundbreaking'. However, this data comes from an extremely small, non-randomized study and does not address the company's dire financial situation. The company faces a locked-in $27 million annual royalty floor starting April 2026, against only $3.1 million in quarterly revenue and $3.5 million in cash. With $45.1 million in total liabilities and a quarterly burn of $6.1 million, the probability of severe dilution or equity wipeout remains very high. This press release appears designed to buoy sentiment ahead of a likely restructuring or distressed financing.

Implication

The clinical data, while encouraging, does nothing to alter Jaguar's impending liquidity crisis. The company must still renegotiate or default on its royalty obligations, and given its weak negotiating position, equity holders are likely to be severely diluted or wiped out. This news may provide short-term price support but is unlikely to attract the large, upfront partnership needed for survival. The core thesis remains that Jaguar cannot repay its fixed obligations without catastrophic equity damage. Therefore, any speculative position should be sized for total loss, and investors should exit on any strength unless a binding restructuring is announced.

Thesis delta

The ESPGHAN data marginally supports the orphan intestinal failure thesis but does not shift the overwhelming liquidity risk. The bear case (55% probability, $0.10 value) remains the most likely outcome, while the bull case (10% probability, $3.00 value) would require far more than early-stage data. The thesis delta is negligible—the financial cliff overshadows any incremental clinical progress.